secwatch.observer — SEC 8-K summary
======================================

Issuer:     Odyssey Therapeutics, Inc. (ODTX)
CIK:        0001882782
Form:       8-K
Filed at:   2026-06-17T20:45:18+00:00
Accession:  0001193125-26-274291
Event type: earnings
Sentiment:  neutral
Materiality: 0.60
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Odyssey Therapeutics Q1 net loss $38.3M; pro-forma cash $464M; positive OD-001 data
--------------------------------------------------------------------------------

- Cash and securities $175.7M at Mar 31, 2026; pro-forma cash $464.4M after IPO net proceeds of $288.7M.
- Net loss of $38.3M for Q1 2026, comparable to $38.4M in Q1 2025.
- R&D expenses $32.3M (down $6.5M YoY); G&A $7.4M (down $0.6M YoY).
- Phase 2a proof-of-concept for OD-001: 27% clinical remission, 61% clinical response in UC.
- Plan to launch Phase 2b monotherapy and Phase 2a combo trial with vedolizumab in H2 2026; data H2 2027.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1882782/000119312526274291/0001193125-26-274291-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1882782/000119312526274291/odtx-20260617.htm
  HTML page:      https://secwatch.observer/filing/0001193125-26-274291

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer